Brooklyn Historical Income Statement

BTX
 Stock
  

USD 0.68  0.04  6.25%   

Historical analysis of Brooklyn Immunotherapeuti income statement accounts such as Cost of Revenue of 9.2 M, Gross Profit of 12.2 M or Interest Expense of 314.2 K can show how well Brooklyn Immunotherapeutics performed in making a profits. Evaluating Brooklyn Immunotherapeuti income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Brooklyn Immunotherapeuti's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Brooklyn Immunotherapeuti latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Brooklyn Immunotherapeuti is a good buy for the upcoming year.
Continue to Trending Equities.
  
Refresh

Brooklyn Immunotherapeuti Net Income

(125.77 Million)

About Brooklyn Income Statement Analysis

Brooklyn Immunotherapeuti Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Brooklyn Immunotherapeuti shareholders. The income statement also shows Brooklyn investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Brooklyn Immunotherapeuti Income Statement Chart

Brooklyn Immunotherapeutics Income Statement is one of the three primary financial statements used for reporting Brooklyn's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brooklyn Immunotherapeuti revenue and expense. Brooklyn Immunotherapeuti Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Brooklyn Immunotherapeutics minus its cost of goods sold. It is profit before Brooklyn Immunotherapeuti operating expenses, interest payments and taxes. Gross profit is also known as gross margin. Aggregate revenue Revenues less cost of revenue [CoR] directly attributable to the revenue generation activity.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Brooklyn Immunotherapeuti financial statement analysis. It represents the amount of money remaining after all of Brooklyn Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.

Preferred Dividends Income Statement Impact

Income statement item reflecting dividend payments to preferred stockholders. Subtracted from Net Income to Parent Net Income to obtain Net Income to Common Stockholders Net Income Common Stock.

Revenues

Revenues refers to the total amount of money received by Brooklyn Immunotherapeuti for goods sold or services provided during a certain time period. It also includes all of Brooklyn Immunotherapeuti sales as well as any other increase in Brooklyn Immunotherapeutics equity.Revenues are reported on Brooklyn Immunotherapeuti income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from Brooklyn Immunotherapeuti income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Brooklyn Immunotherapeuti current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.
 2018 2019 2021 2022 (projected)
Interest Expense389 K249 K286.35 K314.17 K
Gross Profit15.27 M12.32 M11.09 M12.18 M

Brooklyn Immunotherapeuti income statement Correlations

Brooklyn Immunotherapeuti Account Relationship Matchups

Brooklyn Immunotherapeuti income statement Accounts

201720182019202020212022 (projected)
Direct Expenses168 K302 K412 K385 K442.75 K541.54 K
Consolidated Income(1.08 M)(259 K)(2.05 M)(7.29 M)(122.55 M)(125.77 M)
Cost of Revenue7.71 M6.75 M8.07 M7.48 M8.61 M9.25 M
Earning Before Interest and Taxes EBIT(513 K)66 K(1.77 M)(7.29 M)(122.48 M)(125.7 M)
Earning Before Interest and Taxes USD(513 K)66 K(1.77 M)(7.29 M)(122.48 M)(125.7 M)
Gross Profit14.6 M14.52 M15.27 M12.32 M11.09 M12.18 M
Interest Expense576 K498 K389 K249 K286.35 K314.17 K
Net Income(1.08 M)(259 K)(2.05 M)(7.29 M)(122.55 M)(125.77 M)
Net Income Common Stock(1.09 M)(275 K)(2.06 M)(7.29 M)(122.56 M)(125.79 M)
Net Income Common Stock USD(1.09 M)(275 K)(2.06 M)(7.29 M)(122.56 M)(125.79 M)
Operating Expenses15.92 M15.06 M14.09 M7.25 M113.73 M122.71 M
Operating Income(1.4 M)203 K(1.77 M)(7.25 M)(113.73 M)(116.72 M)
Revenues22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Revenues USD22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Selling General and Administrative Expense15.59 M14.46 M13.18 M3.3 M14.72 M14.22 M
Weighted Average Shares1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Weighted Average Shares Diluted1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Income Tax Expense66 K(64 K)27 K64 K57.6 K62.15 K

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brooklyn Immunotherapeuti's public news can be used to forecast risks associated with investment in Brooklyn. The trend in average sentiment can be used to explain how an investor holding Brooklyn can time the market purely based on public headlines and social activities around Brooklyn Immunotherapeutics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brooklyn Immunotherapeuti's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brooklyn Immunotherapeuti's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brooklyn Immunotherapeuti's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brooklyn Immunotherapeuti.

Brooklyn Immunotherapeuti Implied Volatility

    
  538.05  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33.7 M
Return On Assets
-0.65
Return On Equity
-17.56
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.